Skip to main content
Funded Studies

Identifying Enzymes to Stimulate Alpha-synuclein Degradation

Study Rationale:
Rab GTPases, a family of small molecules that guide protein movement around cells, are linked to Parkinson's disease (PD). We have identified a group of Rabs with potential roles in stimulating protein clearance and degradation (break down). Here, we will evaluate whether these Rabs can stimulate the degradation of alpha-synuclein, a protein whose accumulation and aggregation (clumping) contributes to the development of PD.

We hypothesize that specific Rab GTPases will stimulate the clearance of alpha-synuclein from sites of contact between neurons (called synapses) and thereby prevent defects in neuronal communication that occur in PD from alpha-synuclein clumping.

Study Design:
We will measure the clearance and degradation of alpha-synuclein in cells using different biochemistry and microscopy methods. We will evaluate whether the expression of specific Rab GTPases can stimulate alpha-synuclein degradation. For any such Rabs, we will use imaging methods to investigate whether their expression in neurons can rescue defects in communication that result from accumulation of alpha-synuclein.

Impact on Diagnosis/Treatment of Parkinson's disease:
This study will identify Rabs that stimulate alpha-synuclein degradation and assess whether they can rescue defects in synapse function caused by alpha-synuclein buildup. Any Rabs with these properties could be targeted by screening for chemical compounds that stimulate their activity.

Next Steps for Development:
If Rabs are identified in this study, the next step will be to test whether their expression in dopamine neurons in the brain (using a virus for delivery) can rescue neurological and behavioral defects in alpha-synuclein pre-clinical models of PD.


  • Clarissa Waites, PhD

    New York, NY United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.